Drugs that contain Voxelotor

1. List of Oxbryta drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10806733 GLOBAL BLOOD THERAPS Substituted benzaldehyde compounds and methods for their use in increasing tissue oxygenation
Dec, 2032

(9 years from now)

US10034879 GLOBAL BLOOD THERAPS Substituted benzaldehyde compounds and methods for their use in increasing tissue oxygenation
Dec, 2032

(9 years from now)

US9018210 GLOBAL BLOOD THERAPS Substituted benzaldehyde compounds and methods for their use in increasing tissue oxygenation
Nov, 2033

(10 years from now)

US9447071 GLOBAL BLOOD THERAPS Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
Feb, 2035

(12 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10017491 GLOBAL BLOOD THERAPS Compounds and uses thereof for the modulation of hemoglobin
Dec, 2032

(9 years from now)

US9248199 GLOBAL BLOOD THERAPS 1:1 adducts of sickle hemoglobin
Jan, 2034

(10 years from now)

US10722502 GLOBAL BLOOD THERAPS Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
Feb, 2035

(12 years from now)

US11452720 GLOBAL BLOOD THERAPS Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
Feb, 2035

(12 years from now)

US11020382 GLOBAL BLOOD THERAPS Dosing regimens for 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
Dec, 2036

(13 years from now)

US10493035 GLOBAL BLOOD THERAPS Tablets comprising 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
Oct, 2037

(14 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Nov 25, 2026
New Chemical Entity Exclusivity (NCE) Nov 25, 2024

NCE-1 date: November, 2023

Market Authorisation Date: 25 November, 2019

Treatment: Treatment of sickle cell disease by administering voxelotor, as recited in claim 1; Treatment of sickle cell disease by administering voxelotor, as recited in claim 2; Treating sickle cell disease by administering voxelotor and another active agent; Treating sickle cell disease by administering 1500 mg of voxelotor orally once daily; Increasing hemoglobin to treat sickle cell disease by administering 1500 mg of voxelotor orally once daily

Dosage: TABLET;ORAL

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in